While concomitant CV8102 and PD-1 blockade treatment did not significantly increase cytokine production in the tumor environment or serum compared with CV8102 treatment alone, significant differences in immune cell activation at both, the tumor site and dLNs were observed. Here, PDCD1 is linked to neoplasm.